All Studies – Demo

This is a demo – in progress.

These pages contain general information on studies associated with the Center. The Data Availability column provides links for obtaining various types of data associated with the study:

  • NIDA Repository: our repository provides clinical datasets and cell lines for some studies.
  • dbGaP: provides genetic datasets such as GWAS and sequencing.
  • Clinical Trials Network: NIDA’s Clinical Trial Network resource provides additional clinical datasets for clinical trials studies.

Note the Subjects column pertains to subjects having DNA from the distributions in our Available Data section.

The only studies with genetic/GWAS data are the dbGaP studies.

StudyPICollectionSubjects with DNAData Availability
Study 01 – Genetics of Opioid DependenceJoel GelernterOpioid-Cocaine Dependence4848NIDA Repository
Study 02 – Mapping Susceptibility Genes for Nicotine DependenceMing D. LiNicotine Dependence1962NIDA Repository
Study 03 – Molecular Genetics of Heroin Dependence in ChinaMing TsuangOpioid Dependence1232NIDA Repository, dbGaP
Study 05 – Addictions, Genotypes, Polymorphisms, and FunctionMary Jeanne KreekOpioid Dependence1751NIDA Repository, dbGaP
Study 06 – The Genetics of Vulnerability to NicotinePamela MaddenNicotine Dependence2663NIDA Repository, dbGaP
Study 07 – An Introduction to the Family Study of CocaineLaura BierutCocaine Dependence1049NIDA Repository
Study 08 – Mu Opioid Receptor Gene in Heroin AddictsLei YuOpioid DependenceCombined with Study 5
Study 09 – Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics ConsortiumOvide PomerleauNicotine Dependence1540NIDA Repository
Study 10 – Pharmacokinetics of Nicotine in TwinsGary SwanNicotine Dependence62NIDA Repository
Study 11 – Adolescent Drug DependenceJohn HewittPolysubstance Dependence1589NIDA Repository
Study 12 – Substance Abuse and the Dopamine System GenesMichael M. YanyukovPolysubstance Dependence470NIDA Repository
Study 13 – Genetics of Cocaine Induced PsychosisJoseph F. CubellsCocaine Dependence230NIDA Repository
Study 14 – Genome-Wide Analysis for Addiction Susceptibility GenesHerb LachmanOpioid Dependence693NIDA Repository, dbGaP
Study 15 – Nicotine DependenceLaura BierutNicotine Dependence3424NIDA Repository
Study 16 – Nicotine DependenceMark LeppertNicotine Dependence917NIDA Repository
Study 17 – Opioid DependenceWade BerrettiniOpioid Dependence200NIDA Repository
Study 18 – Opioid Dependence: Candidate Genes and G x E EffectsElliot NelsonOpioid Dependence1895NIDA Repository
Study 19 – Epidemiological Study of Substance AbuseRob PhilibertPolysubstance Dependence520NIDA Repository
Study 20 – Innovative Approaches for Cocaine PharmacotherapyHenry KranzlerOpioid-Cocaine Dependence219NIDA Repository
Study 21 – Twin Family Study of Vulnerability to Substance AbuseWilliam IaconoPolysubstance DependenceCombined with Study 25
Study 22 – Exploring the Genetic Basis for Drug UseHallam HurtPolysubstance DependenceClosed
Study 23 – Substance Use Disorder Liability: Candidate Gene SystemMichael M. VanyukovPolysubstance Dependence886NIDA Repository
Study 24 – START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START)Wade BerrettiniOpioid Dependence785NIDA Repository, dbGaP
Study 25 – The Genes, Environment, and Development Initiative (GEDI)William IaconoOther6941
5960 (GWAS)
981 (WGS)
Study 26 – The Genes, Environment, and Development Initiative (GEDI)E. Jane CostelloOther784dbGaP
Study 27 – The Genetic Study of Nicotine Dependence in African Americans (AAND)Laura BierutNicotine Dependence1792NIDA Repository
Study 28 – Center on Antisocial Drug Dependence: the Genetics of HIV Risk BehaviorJohn HewittOtherTBA
Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048David A. NielsenCocaine Dependence302Clinical Trials Network
Study 30 – Phase 2: Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Nepicastat for Cocaine DependenceThomas R. KostenCocaine DependenceTBA
Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051John RotrosenSmokescreen615dbGaP, Clinical Trials Network
Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053Kevin GrayOther302Clinical Trials Network
Study 33 – Genome-wide Association Study of HIV-1 Host Genetics Among Injection Drug UsersEric JohnsonOther6207dbGaP
Study 34 – Attention Deficit-Hyperactivity Disorder (ADHD)Robert K. MoyzisOtherTBA
Study 35 – Genetically Informative Smoking Cessation TrialLi-Shiun ChenNicotine Dependence873NIDA Repository
Study 36 – Genetic Dissection in Pedigrees of Substance Use and Mood Disorders ComorbidityNelson B. FreimerOtherTBA
Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder; CTN-0068Madhukar TrivediOther403Clinical Trials Network
Study 38 – Adolescent Brain Cognitive Development (ABCD) StudyOther10217Available at NDA
Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT); CTN-0097Adam BisagaOpioid Dependence302Clinical Trials Network
Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY); CTN-0098Gavin BartOpioid Dependence342Clinical Trials Network
Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; CTN-0100Edward NunesOpioid Dependence2630Clinical Trials Network
Study 42 – Genetics Analysis of Substance Use Disorder Using the Indiana Biobank DataDongbing LaiOtherTBA
Study 43 – Pediatric Imaging, Neurocognition, and Genetics (PING)Terry JerniganOtherTBA
Study 44 – Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2); CTN-0109Madhukar TrivediCocaine DependenceClinical Trials Network
Study 45 – Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB); CTN-0110Steve ShoptawPolysubstance DependenceClinical Trials Network
Study 46 – Advancing Genomics Research of Substance Use Disorders in Latin American PopulationsJanitza Montalvo-Ortiz & Humberto NicoliniPolysubstance DependenceTBA
Study 51 – Genotyping on Smokescreen Microarray ChipJasmin Vassileva & Alexandre TodorovSmokescreen383; 3001dbGaP studies: phs001647, phs001804
Study 52 – Genetic Contribution to the Abuse Liability of OxycodoneJermaine JonesSmokescreen183 dbGaP
Study 53 – The Women’s Interagency HIV Study (WIHS)Brad AouizeratSmokescreen864dbGaP
Study 54 – Genotyping on Smokescreen Microarray ChipDeborah MashSmokescreen365dbGaP
Study 55 – ALIVE Cohort Smokescreen GWASBrion MaherSmokescreen1140dbGaP
Study 56 – Assess the Cardiovascular, Cognitive, and Subjective Effects of Atomoxetine in Combination with IV MethamphetamineEdythe LondonSmokescreen13dbGaP
Study 57 – Neural Systems, Inhibitory Control, and Methamphetamine DependenceEdythe LondonSmokescreen188dbGaP
Study 58 – Early Methamphetamine Abstinence fMRI and Brain FunctionEdythe LondonSmokescreen93dbGaP
Study 59 – Smokescreen; Opioid/Cocaine Use; Antisocial Drug DependenceRobin CorleySmokescreen552dbGaP
Study 60 – Gene-Environment Interactions in COCCaINE Use Disorder: Collaborative Case-Control Initiative in Cocaine AddictionRodrigo Grassi-OliveiraSmokescreen1547dbGaP
Study 61 – Smokescreen; NJD/NID CohortStanley WeissSmokescreendbGaP
Study 62 – Prevention of Viral Hepatitis and HIV in Drug Users – A Hepatitis B Model for HIV and an HB Vaccine Model (DASH)Lu-Yu HwangSmokescreen2225dbGaP
Study 63 – Smokescreen; InC3 Cohort Substance AbusersKimberly PageSmokescreen1887dbGaP
Study 64 – Smokescreen; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)Inga PeterSmokescreen4761dbGaP
Study 65 – Spit for ScienceDanielle DickSmokescreen8040dbGaP